NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submissi ...

NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form ...

Novo Nordisk (NVO) is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.34 billion, while the same for earnings is pinned at 83 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk’s 2024 earnings per share (EPS) declined from $3.28 to $3.16. During the same time frame, the ...

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the company's obesity treatment study results [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Moon v. Novo Nordisk A/S and covers purchasers of Novo Nordisk securities from November 2, 2022, to December 19, 2024 [1]. - Investors have until March 25, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Novo Nordisk executives made false statements about the success of the phase 3 CagriSema study, specifically regarding weight loss outcomes and dosage tolerability [3]. Group 2: Allegations Against Novo Nordisk - The lawsuit alleges that Novo Nordisk misrepresented the reliability of information regarding the CagriSema study's outcomes and failed to disclose critical details about dosage tolerability [3]. - It is claimed that the optimistic projections of achieving at least 25% weight loss were not met, and the study's flexible protocol limited the ability to provide accurate weight loss data [3]. - Following the release of the study results on December 20, 2024, Novo Nordisk's stock price fell nearly 18%, indicating a significant market reaction to the disclosed information [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Novo Nordisk securities during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [6].

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=126285&from=4CLASS PERIOD: November 2, 2022 to Dece ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NVO -1.04%), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area ...

SAN DIEGO, Jan. 31, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period"), have until March 25, 2025 to seek appointment as lead plaintiff of the Novo Nordisk class action lawsuit. Captioned Moon v. Novo Nordisk A/S, No. 25-cv-00713 (D.N.J.), the Novo Nordisk class action lawsuit charges Novo Nordisk as well as certain of ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-for ...

Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1] Group 1: Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [1] - Only 57.3% of patients in the trial were on the highest dosage of CagriSema, as participants were allowed to modify their own dosage during the trial [1] Group 2: Stock Price Impact - Following the press release regarding the trial results, Novo's stock price decreased by $18.44 per share, closing at $85.00 per share [1] Group 3: Class Action Information - Shareholders who purchased shares of NVO during the class period from November 2, 2022, to December 19, 2024, are encouraged to register for a class action lawsuit [2] - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [2]